FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccines (Basel) / Sero-Monitoring of Horses Demonstrates the Equivac® HeV...
Vaccines2021; 9(7); 731; doi: 10.3390/vaccines9070731

Sero-Monitoring of Horses Demonstrates the Equivac® HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres.

Abstract: Hendra virus (HeV) is a high consequence zoonotic pathogen found in Australia. The HeV vaccine was developed for use in horses and provides a One Health solution to the prevention of human disease. By protecting horses from infection, the vaccine indirectly protects humans as well, as horses are the only known source of infection for humans. The sub-unit-based vaccine, containing recombinant HeV soluble G (sG) glycoprotein, was released by Pfizer Animal Health (now Zoetis) for use in Australia at the end of 2012. The purpose of this study was to collate post-vaccination serum neutralising antibody titres as a way of assessing how the vaccine has been performing in the field. Serum neutralization tests (SNTs) were performed on serum samples from vaccinated horses submitted to the laboratory by veterinarians. The SNT results have been analysed, together with age, dates of vaccinations, date of sampling and location. Results from 332 horses formed the data set. Provided horses received at least three vaccinations (consisting of two doses 3-6 weeks apart, and a third dose six months later), horses had high neutralising titres (median titre for three or more vaccinations was 2048), and none tested negative.
Get Full Text
Publication Date: 2021-07-02 PubMed ID: 34358146PubMed Central: PMC8310234DOI: 10.3390/vaccines9070731Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article investigates the effectiveness of the Hendra virus (HeV) vaccine in horses in Australia. The research indicates that the vaccine has been successful in equipping horses with high neutralizing antibody titres, thus providing indirect protection to humans against the zoonotic pathogen, given that horses are the only known source of human infection.

Introduction to Hendra Virus and the HeV Vaccine

  • The Hendra virus (HeV) is a pathogen found in Australia that can transmit from animals to humans, resulting in severe and often fatal respiratory and neurological illnesses.
  • The Equivac HeV vaccine, developed for use in horses, offers a One Health solution to this problem. By vaccinating horses–the only known source of the virus in humans–the spread of the disease to human populations is indirectly prevented.
  • The vaccine, introduced by Pfizer Animal Health (now Zoetis) in late 2012, is sub-unit-based and contains the recombinant HeV soluble G (sG) glycoprotein.

Purpose and Methodology of the Study

  • The objective of this study was to evaluate the effectiveness of the HeV vaccine in horses.
  • Post-vaccination serum neutralising antibody titres — a standard measure of a vaccine’s performance — were collated and analyzed. Serum Neutralisation Tests (SNTs) were conducted on samples drawn from vaccinated horses and sent to the laboratory by veterinarians.
  • Data related to horses’ age, vaccination dates, sampling dates, and location was also gathered and analyzed. A total of 332 horses were sampled for the study.

Findings

  • The study found that horses that received at least three doses of the vaccine exhibited high neutralising titres. The median titre for horses with three or more vaccinations was 2048.
  • None of the horses that had received at least three vaccine doses tested negative, indicating a high vaccine-induced immunity against the Hendra virus.
  • The study’s results affirm the high effectiveness of the Equivac HeV vaccine in equipping horses with sufficient antibodies against the Hendra virus, thereby indirectly safeguarding human health.

Cite This Article

APA
Halpin K, Graham K, Durr PA. (2021). Sero-Monitoring of Horses Demonstrates the Equivac® HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres. Vaccines (Basel), 9(7), 731. https://doi.org/10.3390/vaccines9070731

Publication

Vaccines
ISSN: 2076-393X
NlmUniqueID: 101629355
Country: Switzerland
Language: English
Volume: 9
Issue: 7
PII: 731

Researcher Affiliations

Halpin, Kim
  • Australian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), 5 Portarlington Road, East Geelong, VIC 3219, Australia.
Graham, Kerryne
  • Australian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), 5 Portarlington Road, East Geelong, VIC 3219, Australia.
Durr, Peter A
  • Australian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), 5 Portarlington Road, East Geelong, VIC 3219, Australia.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 30 references
  1. Halpin K, Young PL, Field HE, Mackenzie JS. Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus.. J Gen Virol 2000 Aug;81(Pt 8):1927-1932.
    doi: 10.1099/0022-1317-81-8-1927pubmed: 10900029google scholar: lookup
  2. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, Westbury H, Hiley L, Selvey L, Rodwell B. A morbillivirus that caused fatal disease in horses and humans.. Science 1995 Apr 7;268(5207):94-7.
    doi: 10.1126/science.7701348pubmed: 7701348google scholar: lookup
  3. Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I, Moore F, Taylor C, Kung YH, Field H. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008.. Emerg Infect Dis 2010 Feb;16(2):219-23.
    doi: 10.3201/eid1602.090552pmc: PMC2957996pubmed: 20113550google scholar: lookup
  4. Baldock FC, Douglas IC, Halpin K, Field HE, Young PL, Black PF. Epidemiological investigations into the 1994 equine morbillivirus outbreaks in Queensland, Australia.. Singap. Vet. J. 1996;20:57–61.
  5. Taylor C, Playford EG, McBride WJ, McMahon J, Warrilow D. No evidence of prolonged Hendra virus shedding by 2 patients, Australia.. Emerg Infect Dis 2012 Dec;18(12):2025-7.
    doi: 10.3201/eid1812.120722pmc: PMC3557865pubmed: 23171522google scholar: lookup
  6. Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, Yamada M, White J, Payne J, Feng YR, Chan YP, Broder CC. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge.. Vaccine 2011 Aug 5;29(34):5623-30.
    doi: 10.1016/j.vaccine.2011.06.015pmc: PMC3153950pubmed: 21689706google scholar: lookup
  7. Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC, Feldmann H, Geisbert TW. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.. Sci Transl Med 2012 Aug 8;4(146):146ra107.
    doi: 10.1126/scitranslmed.3004241pmc: PMC3516289pubmed: 22875827google scholar: lookup
  8. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Choudhary A, Wang LF, Eaton BT, Broder CC. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.. J Virol 2005 Jun;79(11):6690-702.
    doi: 10.1128/JVI.79.11.6690-6702.2005pmc: PMC1112112pubmed: 15890907google scholar: lookup
  9. Middleton D, Pallister J, Klein R, Feng YR, Haining J, Arkinstall R, Frazer L, Huang JA, Edwards N, Wareing M, Elhay M, Hashmi Z, Bingham J, Yamada M, Johnson D, White J, Foord A, Heine HG, Marsh GA, Broder CC, Wang LF. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health.. Emerg Infect Dis 2014 Mar;20(3):372-9.
    doi: 10.3201/eid2003.131159pmc: PMC3944873pubmed: 24572697google scholar: lookup
  10. Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, Pallister J, Geisbert TW, Bossart KN, Wang LF. A treatment for and vaccine against the deadly Hendra and Nipah viruses.. Antiviral Res 2013 Oct;100(1):8-13.
    doi: 10.1016/j.antiviral.2013.06.012pmc: PMC4418552pubmed: 23838047google scholar: lookup
  11. Australian Pesticides and Veterinary Medicines Authority Hendra Virus Vaccine Product Registration. [(accessed on 30 April 2021)]; Available online: https://apvma.gov.au/node/12876.
  12. Manyweathers J, Field H, Longnecker N, Agho K, Smith C, Taylor M. "Why won't they just vaccinate?" Horse owner risk perception and uptake of the Hendra virus vaccine.. BMC Vet Res 2017 Apr 13;13(1):103.
    doi: 10.1186/s12917-017-1006-7pmc: PMC5390447pubmed: 28407738google scholar: lookup
  13. Tan R, Hodge A, Klein R, Edwards N, Huang JA, Middleton D, Watts SP. Virus-neutralising antibody responses in horses following vaccination with Equivac® HeV: a field study.. Aust Vet J 2018 May;96(5):161-166.
    doi: 10.1111/avj.12694pubmed: 29691855google scholar: lookup
  14. Hafi A, Gomboso J, Hean R, Scott F, Arthur T, Rahman N. Estimating the Value of Australian Biosecurity Arrangements for Equine Influenza since the 2007 Outbreak. ABARES Research Report Canberra, December.
    doi: 10.25814/sqnq-k268google scholar: lookup
  15. Barrett RS, Wiethoelter A, Halpin K. The Hendra virus vaccine: perceptions regarding the role of antibody titre testing.. Aust Vet J 2021 Sep;99(9):412-418.
    doi: 10.1111/avj.13099pubmed: 34151419google scholar: lookup
  16. Roberts B, Eby P, Tsang SM, Sheherazade. Pteropus alecto. The IUCN Red List of Threatened Species 2017: E.T18715A22080057.
    doi: 10.2305/IUCN.UK.2017-2.RLTS.T18715A22080057.engoogle scholar: lookup
  17. Roberts B, Eby P, Westcott D. Pteropus conspicillatus. The IUCN Red List of Threatened Species 2020: E.T18721A22080456.
    doi: 10.2305/IUCN.UK.2020-3.RLTS.T18721A22080456.engoogle scholar: lookup
  18. Lunney D, Richards G, Dickman C. Pteropus poliocephalus. The IUCN Red List of Threatened Species 2008: E.T18751A8554062.
    doi: 10.2305/IUCN.UK.2008.RLTS.T18751A8554062.engoogle scholar: lookup
  19. Eby P, Roberts B. Pteropus scapulatus. The IUCN Red List of Threatened Species 2016: E.T18758A22087637.
    doi: 10.2305/IUCN.UK.2016-1.RLTS.T18758A22087637.engoogle scholar: lookup
  20. McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D, Feng YR, Broder CC, Wang LF, Bossart KN. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats.. Vaccine 2008 Jul 23;26(31):3842-52.
    doi: 10.1016/j.vaccine.2008.05.016pmc: PMC6186147pubmed: 18556094google scholar: lookup
  21. World Health Organization. WHO Expert Consultation on Rabies, 2nd Report. World Health Organization Technical Report Series 2013 (No 982).
  22. OIE. Rabies (Infection with Rabies Virus and other Lyssaviruses). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2019.
  23. Johnson N, Cunningham AF, Fooks AR. The immune response to rabies virus infection and vaccination.. Vaccine 2010 May 21;28(23):3896-901.
    doi: 10.1016/j.vaccine.2010.03.039pubmed: 20368119google scholar: lookup
  24. Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM. NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination.. J Immunol 2010 Sep 1;185(5):2808-18.
    doi: 10.4049/jimmunol.1000844pubmed: 20679529google scholar: lookup
  25. Mansfield KL, Andrews N, Goharriz H, Goddard T, McElhinney LM, Brown KE, Fooks AR. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans.. Vaccine 2016 Nov 21;34(48):5959-5967.
    doi: 10.1016/j.vaccine.2016.09.058pubmed: 27997343google scholar: lookup
  26. Paillot R, El-Hage CM. The Use of a Recombinant Canarypox-Based Equine Influenza Vaccine during the 2007 Australian Outbreak: A Systematic Review and Summary.. Pathogens 2016 Jun 10;5(2).
    doi: 10.3390/pathogens5020042pmc: PMC4931393pubmed: 27294963google scholar: lookup
  27. Mumford JA, Jessett DM, Rollinson EA, Hannant D, Draper ME. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines.. Vet Rec 1994 Feb 12;134(7):158-62.
    doi: 10.1136/vr.134.7.158pubmed: 8160328google scholar: lookup
  28. Soboll G, Hussey SB, Minke JM, Landolt GA, Hunter JS, Jagannatha S, Lunn DP. Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC) vaccination.. Vet Immunol Immunopathol 2010 May 15;135(1-2):100-107.
    doi: 10.1016/j.vetimm.2009.11.007pubmed: 20018384google scholar: lookup
  29. McNabb L, Barr J, Crameri G, Juzva S, Riddell S, Colling A, Boyd V, Broder C, Wang LF, Lunt R. Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus.. J Virol Methods 2014 May;200:22-8.
    doi: 10.1016/j.jviromet.2014.01.010pubmed: 24508193google scholar: lookup
  30. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Springer International Publishing 2nd ed. Cham, Switzerland: 2015. p. 582.

Citations

This article has been cited 10 times.
  1. Kropich-Grant JN, Wiley KE, Manyweathers J, Thompson KR, Brookes VJ. Communication Interventions and Assessment of Drivers for Hendra Virus Vaccination Uptake. Vaccines (Basel) 2023 May 4;11(5).
    doi: 10.3390/vaccines11050936pubmed: 37243040google scholar: lookup
  2. Balkema-Buschmann A, Fischer K, McNabb L, Diederich S, Singanallur NB, Ziegler U, Keil GM, Kirkland PD, Penning M, Sadeghi B, Marsh G, Barr J, Colling A. Serological Hendra Virus Diagnostics Using an Indirect ELISA-Based DIVA Approach with Recombinant Hendra G and N Proteins. Microorganisms 2022 May 25;10(6).
    doi: 10.3390/microorganisms10061095pubmed: 35744614google scholar: lookup
  3. Pigeaud DD, Borisevich V, Agans KN, Harrison MB, O'Toole R, Martinez J, Dobias NS, Woolsey C, Fenton KA, Geisbert TW, Cross RW. A single-cycle recombinant VSV vaccine displaying the Hendra virus glycoprotein uniformly protects against Hendra and Nipah virus challenge. NPJ Vaccines 2026 Jan 3;11(1):21.
    doi: 10.1038/s41541-025-01343-2pubmed: 41484102google scholar: lookup
  4. White J, Thompson K, van den Berg D, O'Neill G, Mendez DH, Talwar J, Degeling C, Forsythe R, Durrheim DN. 'Pretty devastating': exploring horse owner and veterinarian lived experiences of the equine Hendra virus. Front Vet Sci 2025;12:1661615.
    doi: 10.3389/fvets.2025.1661615pubmed: 41357753google scholar: lookup
  5. Sikkema RS, Koopmans M. Viral emergence and pandemic preparedness in a One Health framework. Nat Rev Microbiol 2026 Jan;24(1):29-44.
    doi: 10.1038/s41579-025-01243-1pubmed: 41044181google scholar: lookup
  6. van den Hurk S, Yondo A, Velayudhan BT. Laboratory Diagnosis of Hendra and Nipah: Two Emerging Zoonotic Diseases with One Health Significance. Viruses 2025 Jul 17;17(7).
    doi: 10.3390/v17071003pubmed: 40733619google scholar: lookup
  7. McNabb L, McMahon A, Woube EG, Agnihotri K, Colling A, Broder CC, Kucinskaite-Kodze I, Petraityte-Burneikiene R, Bowden TR, Halpin K. Development and Validation of a Differentiating Infected from Vaccinated Animals (DIVA) Enzyme-Linked Immunosorbent Assay (ELISA) Strategy for Distinguishing Between Hendra-Infected and Vaccinated Horses. Viruses 2025 Feb 28;17(3).
    doi: 10.3390/v17030354pubmed: 40143282google scholar: lookup
  8. Sabir AJ, Rong L, Broder CC, Amaya M. Cedar virus biology and its applications as a surrogate for highly pathogenic henipaviruses. Cell Insight 2024 Aug;3(4):100181.
    doi: 10.1016/j.cellin.2024.100181pubmed: 39967899google scholar: lookup
  9. Pigeaud DD, Geisbert TW, Woolsey C. Animal Models for Henipavirus Research. Viruses 2023 Sep 22;15(10).
    doi: 10.3390/v15101980pubmed: 37896758google scholar: lookup
  10. Pollak NM, Marsh GA, Olsson M, McMillan D, Macdonald J. Rapid, sensitive, and specific, low-resource molecular detection of Hendra virus. One Health 2023 Jun;16:100504.
    doi: 10.1016/j.onehlt.2023.100504pubmed: 37363221google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.